PDCD1 and neoplasm: Anti-Programmed Cell Death Protein 1 (PD-1) antibodies achieve their anti-tumour effect through an interruption of the PD-1-mediated inhibition of T-cells in peripheral tissue performed by Programmed Cell Death Ligand 1 (PD-L1) expressing tumour cells [5].